GLP-1 Coverage by State
Coverage decisions are made state by state and change often - several states added Medicaid GLP-1 coverage and then rescinded it within the same year once actual spending came in over budget. This table pulls directly from the same state-by-state data used throughout the site, so it updates whenever that data does.
| Medicaid expansion | |||
|---|---|---|---|
| Alabama → | No | No | Not expanded |
| Alaska → | No | Limited | Expanded |
| Arizona → | No | Limited | Expanded |
| Arkansas → | No | No | Expanded |
| California → | No | Covers | Expanded |
| Colorado → | No | Covers | Expanded |
| Connecticut → | No | Covers | Expanded |
| Delaware → | No | Limited | Expanded |
| Florida → | No | No | Not expanded |
| Georgia → | No | Limited | Not expanded |
| Hawaii → | No | Covers | Expanded |
| Idaho → | No | No | Expanded |
| Illinois → | No | Covers | Expanded |
| Indiana → | No | Limited | Expanded |
| Iowa → | No | Covers | Expanded |
| Kansas → | No | Limited | Not expanded |
| Kentucky → | No | Limited | Expanded |
| Louisiana → | No | No | Expanded |
| Maine → | No | Limited | Expanded |
| Maryland → | No | Covers | Expanded |
| Massachusetts → | No | Covers | Expanded |
| Michigan → | No | Limited | Expanded |
| Minnesota → | No | Covers | Expanded |
| Mississippi → | Covers | No | Not expanded |
| Missouri → | No | No | Expanded |
| Montana → | No | Limited | Expanded |
| Nebraska → | No | No | Expanded |
| Nevada → | No | Limited | Expanded |
| New Hampshire → | No | Covers | Expanded |
| New Jersey → | No | Covers | Expanded |
| New Mexico → | No | Limited | Expanded |
| New York → | No | Limited | Expanded |
| North Carolina → | No | No | Expanded |
| North Dakota → | No | No | Expanded |
| Ohio → | No | Limited | Expanded |
| Oklahoma → | No | No | Expanded |
| Oregon → | No | Covers | Expanded |
| Pennsylvania → | No | Covers | Expanded |
| Rhode Island → | No | Covers | Expanded |
| South Carolina → | No | No | Not expanded |
| South Dakota → | No | No | Expanded |
| Tennessee → | Covers | Limited | Not expanded |
| Texas → | No | No | Not expanded |
| Utah → | No | Covers | Expanded |
| Vermont → | No | Covers | Expanded |
| Virginia → | Covers | Covers | Expanded |
| Washington → | No | Covers | Expanded |
| West Virginia → | No | No | Expanded |
| Wisconsin → | No | Limited | Not expanded |
| Wyoming → | No | No | Not expanded |
Frequently asked questions
How many states cover GLP-1s under Medicaid for weight loss?
As of July 2026, only 3 of 50 states cover a GLP-1 (Wegovy or Zepbound) under Medicaid specifically for weight loss as a standalone indication. Most state Medicaid programs cover GLP-1s only for type 2 diabetes, and route weight-loss patients to a diabetes-indicated drug (Ozempic, Mounjaro) only if they have a qualifying diagnosis. Coverage is unusually volatile in both directions - several states added coverage and then rescinded it within the same year as spending came in far above budget.
Why do so few states cover it?
Cost. Every state that has published actual spending data has found GLP-1 weight-loss coverage costs dramatically more than initially budgeted - Delaware's state employee plan hit over $14 million in a year against a $2 million budget, for one documented example. States weighing coverage generally run an actuarial model comparing near-term drug spend against projected long-term savings from fewer cardiovascular events, less type 2 diabetes progression, and less bariatric surgery - and near-term budget pressure has been winning in most states that have made a decision either way in 2025-2026.
What does "state employee plan covers" mean if I'm not a state employee?
Nothing directly - but it's a useful leading indicator. A state's own employee health plan is usually the first place a state government tests GLP-1 coverage before any Medicaid decision, and its outcome (does it get expensive fast, does the legislature push back) often predicts what happens next in that state's Medicaid program. As of July 2026, 18 state employee plans cover weight-loss GLP-1s outright.
Does Medicaid expansion status affect GLP-1 coverage?
Not directly, but the two questions get conflated. "Medicaid expansion" refers to a state's decision to extend Medicaid eligibility to more low-income adults under the ACA - it is a separate policy question from whether that state's Medicaid formulary covers GLP-1s for weight loss once someone is enrolled. A state can have expanded Medicaid broadly and still exclude weight-loss GLP-1s from its drug formulary, and vice versa.
What if my state does not cover GLP-1s under Medicaid?
Check whether you qualify under a diabetes indication instead (Ozempic or Mounjaro, not Wegovy or Zepbound), since nearly every state Medicaid program covers GLP-1s for type 2 diabetes even where weight-loss coverage is excluded. If that path is closed, direct manufacturer self-pay (NovoCare for Wegovy, LillyDirect for Zepbound) remains available at cash prices regardless of your insurance status - Medicaid enrollees cannot use the manufacturer copay savings cards (federally excluded), but can use the direct self-pay cash price like anyone else.
Related guides
Stay ahead of every GLP-1 development
We'll email you when something actually matters: new FDA approvals (Foundayo, CagriSema, retatrutide), pricing drops at LillyDirect/NovoCare, telehealth deals, clinical trial results, FDA recalls, and insurance policy changes. ~1-2 emails/month. No filler.